Low-dose rapamycin and cerebral blood flow in cognitively normal middle-aged adults by APOE genotype (pilot)
Cerebral blood flow rose >15% in APOE4 carriers (n=9) but not non-carriers (n=14); no placebo arm, 4 weeks, surrogate endpoint.
Evidence
4/10
Emerging Evidence
Sample
23
subjects
Duration
4 weeks
study period
Journal
Journal of Cerebral Blood Flow & Metabolism
Sep 2026
Full Abstract
Single-arm pilot of rapamycin 1 mg/day for 4 weeks in cognitively normal adults aged 45-65, stratified by APOE4 status.
Key Findings
- 01
CBF increased >15% across multiple regions in APOE4 carriers
- 02
No significant CBF change in non-carriers
- 03
Favourable metabolic/inflammatory shifts with minimal adverse events
Structured Methods
- Study Design
- Clinical Trial
- Sample Size
- 23 subjects
- Study Duration
- 4 weeks
- Methodology
- Open-label single-arm pilot, APOE-stratified
- Limitations
- No control arm; 9 carriers; 4-week duration; perfusion is a surrogate for cognition; sex-specific press claims not supported by the abstract.
Citations & References
Unknown authors (2026). Low-dose rapamycin and cerebral blood flow in cognitively normal middle-aged adults by APOE genotype (pilot). Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1177/0271678X261490342
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation